Evidence map›Paper›PMID 27329729›Full record

ArticleOncotarget2016

Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.

Anne-Marie Makhlouf, Zhanna Chitikova, Marc Pusztaszeri, Margaret Berczy, Celine Delucinge-Vivier, Frederic Triponez, Patrick Meyer, Jacques Philippe, Charna Dibner

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anne-Marie MakhloufDepartment of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Zhanna ChitikovaDepartment of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Marc PusztaszeriDivision of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.
Margaret BerczyDivision of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.
Celine Delucinge-VivieriGE3 Genomics Platform, University of Geneva, Geneva, Switzerland.
Frederic TriponezDepartment of Thoracic and Endocrine Surgery, University Hospital of Geneva, Geneva, Switzerland.
Patrick MeyerDivision of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital of Geneva, Geneva, Switzerland.
Jacques PhilippeDepartment of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Charna DibnerDepartment of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for preoperative biomarkers for thyroid malignancies, in particular for follicular thyroid carcinoma (FTC) diagnostics, is of utmost clinical importance. We thus aimed at screening for potential biomarker candidates for FTC. To evaluate dynamic alterations in molecular patterns as a function of thyroid malignancy progression, a comparative analysis was conducted in clinically distinct subgroups of FTC and poorly differentiated thyroid carcinoma (PDTC) nodules. NanoString analysis of FFPE samples was performed in 22 follicular adenomas, 56 FTC and 25 PDTC nodules, including oncocytic and non-oncocytic subgroups. The expression levels of CHEK1, c-KIT, SLC26A4, TG and TPO were significantly altered in all types of thyroid carcinomas. Based on collective changes of these biomarkers which correlating among each other, a predictive score has been established, allowing for discrimination between benign and FTC samples with high sensitivity and specificity. Additional transcripts related to thyroid function, cell cycle, circadian clock, and apoptosis regulation were altered in the more aggressive oncocytic subgroups only, with expression levels correlating with disease progression. Distinct molecular patterns were observed for oncocytic and non-oncocytic FTCs and PDTCs. A predictive score correlation coefficient based on collective alterations of identified here biomarkers might help to improve the preoperative diagnosis of FTC nodules.

Indexed as

TranscriptomeAdenocarcinoma, FollicularAutoantigensBiomarkers, TumorCheckpoint Kinase 1Gene Expression ProfilingHumansIodide PeroxidaseIron-Binding ProteinsMembrane Transport ProteinsMicrofilament ProteinsMuscle ProteinsProto-Oncogene Proteins c-kitSulfate TransportersThyroid NeoplasmsAutoantigensBiomarkers, TumorCheckpoint Kinase 1CHEK1 protein, humanIodide PeroxidaseIron-Binding ProteinsMembrane Transport ProteinsMicrofilament ProteinsMuscle ProteinsProto-Oncogene Proteins c-kitSLC26A4 protein, humanSulfate TransportersTPO protein, humantransgelindiagnostic biomarkersfollicular thyroid carcinomaNanoString analysispoorly differentiated thyroid carcinoma

Identifiers

PMID27329729
PMCPMC5216760
OpenAlexW2442623390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.